Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02076191 · ClinicalTrials.gov registry record · Phase 1
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
A Phase 1 study, sponsored by John Mascarenhas.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT02076191 is a Phase 1 study that has completed, run by John Mascarenhas. The registered enrollment target is 49 participants.
The verdict
NCT02076191, a Phase 1 study, has completed, sponsored by John Mascarenhas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of ruxolitinib at different dose levels in combination with decitabine and the effectiveness of ruxolitinib in combination with decitabine in patients with accelerated or blast phase Myeloproliferative Neoplasm (MPN), which is a group of diseases of the bone marrow in which excess cells are produced. Ruxolitinib is a drug that is approved by the Federal Drug Administration (FDA) for the treatment of patients with advanced forms of myelofibrosis. It inhibits the Jak proteins that are often abnormal in MPN. A recent clinical study showed that ruxolitinib treatment could put some patients with this disease into remission. Decitabine is a chemotherapy, approved by the Federal Drug Administration (FDA), that has been used to treat acute leukemia. It works in some patients, but most patients with accelerated and blastic MPN do not respond to treatment. Ruxolitinib and decitabine will be combined in this study to find out what dose of the two medicines are safe together. Using Ruxolitinib in combination with Decitabine is experimental. The investigators want to find out what effects, good and/or bad it has on the patient and the disease.
Interventions
- DRUG Decitabine
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2014-02 |
| Est. Completion | 2018-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02076191
The ClinicalTrials.gov registry entry for NCT02076191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Mascarenhas, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT02076191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02076191 about?
NCT02076191 is a clinical study titled "Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML". The purpose of this study is to test the safety and tolerability of ruxolitinib at different dose levels in combination with decitabine and the effectiveness of ruxolitinib in combination with decitabine in patients with accelerated or blast phase Myeloproliferative Neoplasm (MPN), which is a group ...
What is the current status of trial NCT02076191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2014-02. Estimated completion is 2018-07-20.
What interventions are being tested in trial NCT02076191?
The interventions under investigation include: Decitabine (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT02076191?
This trial is sponsored by John Mascarenhas, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.